Ixazomib, daratumumab and low-dose dexamethasone in intermediate-fit patients with newly diagnosed multiple myeloma: an open-label phase 2 trial

被引：6

作者：

Groen, Kaz ^{[1
,2
]}

Stege, Claudia A. M. ^{[1
,2
]}

Nasserinejad, Kazem ^{[3
,4
]}

de Heer, Koen ^{[5
]}

van Kampen, Roel J. W. ^{[6
]}

Leys, Rineke B. L. ^{[7
]}

Thielen, Noortje ^{[8
]}

Westerman, Matthijs ^{[9
]}

Wu, Ka-Lung ^{[10
]}

Ludwig, Inge ^{[11
]}

Issa, Djamila E. ^{[12
]}

Velders, Gerjo A. ^{[13
]}

Vekemans, Marie-Christiane ^{[14
]}

Timmers, Gert-Jan ^{[15
]}

de Boer, Fransien ^{[16
]}

Tick, Lidwine W. ^{[17
]}

Verbrugge, Annelies ^{[3
]}

Buitenhuis, Danny ^{[3
]}

Cunha, Sonia M. ^{[3
]}

van der Spek, Ellen ^{[18
]}

de Waal, Esther G. M. ^{[19
]}

Sohne, Maaike ^{[20
]}

Sonneveld, Pieter ^{[21
]}

Nijhof, Inger S. ^{[20
]}

Klein, Saskia K. ^{[22
,23
]}

van der Donk, Niels W. C. J. ^{[1
,2
]}

Levin, Mark-David ^{[24
]}

Ypma, Paula F. ^{[25
]}

Zweegman, Sonja ^{[1
,2
,26
]}

机构：

[1] Vrije Univ Amsterdam, Dept Hematol, Amsterdam UMC, Amsterdam, Netherlands

[2] Canc Ctr Amsterdam, Treatment & Qual Life, Amsterdam, Netherlands

[3] Erasmus MC Canc Inst, HOVON Data Ctr, Dept Hematol, Rotterdam, Netherlands

[4] Cytel Inc, Therapeut Dev Team, Innovat Stat Consulting, Waltham, MA USA

[5] Flevoziekenhuis, Dept Internal Med, Almere, Netherlands

[6] Zuyderland Hosp, Dept Internal Med, Sittard Geleen, Netherlands

[7] Maasstad Hosp, Dept Internal Med, Rotterdam, Netherlands

[8] Diakonessen Hosp, Dept Internal Med, Utrecht, Netherlands

[9] Northwest Clin, Dept Internal Med, Alkmaar, Netherlands

[10] ZNA Stuivenberg, Dept Hematol, Antwerp, Belgium

[11] Ziekenhuis Bernhoven, Dept Internal Med, Uden, Netherlands

[12] Jeroen Bosch Hosp, Dept Internal Med, Den Bosch, Netherlands

[13] Gelderse Vallei, Dept Internal Med, Ede, Netherlands

[14] UCL, Dept Hematol, Clin Univ St Luc, Brussels, Belgium

[15] Amstelland Hosp, Dept Internal Med, Amstelveen, Netherlands

[16] Ikazia Hosp, Dept Internal Med, Rotterdam, Netherlands

[17] Maxima Med Ctr, Dept Internal Med, Eindhoven, Netherlands

[18] Rijnstate Hosp, Dept Internal Med, Arnhem, Netherlands

[19] Med Ctr Leeuwarden, Dept Internal Med, Leeuwarden, Netherlands

[20] Antonius Ziekenhuis, Dept Internal Med, Nieuwegein, Netherlands

[21] Erasmus MC Canc Inst, Dept Hematol, Rotterdam, Netherlands

[22] Meander Med Ctr, Dept Internal Med, Amersfoort, Netherlands

[23] Univ Med Ctr Groningen, Dept Hematol, Groningen, Netherlands

[24] Albert Schweitzer Hosp, Dept Internal Med, Dordrecht, Netherlands

[25] Haga Hosp, Dept Internal Med, The Hague, Netherlands

[26] Dept Hematol, Boelelaan 1117, NL-1081 HV Amsterdam, Netherlands

来源：

ECLINICALMEDICINE | 2023年 / 63卷

关键词：

Multiple myeloma; Elderly; Daratumumab; Ixazomib; Intermediate-fit; IMWG frailty index; STEM-CELL TRANSPLANTATION; ORAL IXAZOMIB; LENALIDOMIDE; MAINTENANCE; BORTEZOMIB; SURVIVAL; THALIDOMIDE; PREDNISONE; MELPHALAN; CONSENSUS;

D O I：

10.1016/j.eclinm.2023.102167

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Background The outcome of non-transplant eligible newly diagnosed multiple myeloma (NDMM) patients is heterogeneous, partly depending on frailty level. The aim of this study was to prospectively investigate the efficacy and safety of Ixazomib-Daratumumab-low-dose dexamethasone (Ixa-Dara-dex) in NDMM intermediate-fit patients. Methods In this phase II multicenter HOVON-143 study, IMWG Frailty index based intermediate-fit patients, were treated with 9 induction cycles of Ixa-Dara-dex, followed by maintenance with ID for a maximum of 2 years. The primary endpoint was overall response rate on induction treatment. Patients were included from October 2017 until May 2019. Trial Registration Number: NTR6297. Findings Sixty-five patients were included. Induction therapy resulted in an overall response rate of 71%. Early mortality was 1.5%. At a median follow-up of 41.0 months, median progression-free survival (PFS) was 18.2 months and 3-year overall survival 83%. Discontinuation of therapy occurred in 77% of patients, 49% due to progression, 9% due to toxicity, 8% due to incompliance, 3% due to sudden death and 8% due to other reasons. Dose modifications of ixazomib were required frequently (37% and 53% of patients during induction and maintenance, respectively), mainly due to, often low grade, polyneuropathy. During maintenance 23% of patients received daratumumab alone. Global quality of life (QoL) improved significantly and was clinically relevant, which persisted during maintenance treatment. Interpretation Ixazomib-Daratumumab-low-dose dexamethasone as first line treatment in intermediate -fit NDMM patients is safe and improves global QoL. However, efficacy was limited, partly explained by ixazomib-induced toxicity, hampering long term tolerability of this 3-drug regimen. This highlights the need for more efficacious and tolerable regimens improving the outcome in vulnerable intermediate -fit patients.

引用

页数：12

共 50 条

[1] Ixazomib, Daratumumab and Low Dose Dexamethasone in Intermediate-Fit Patients with Newly Diagnosed Multiple Myeloma (NDMM); Results of Induction Treatment of the Phase II HOVON 143 Study
Groen, Kaz
Stege, Claudia A. M.
Nasserinejad, Kazem
de Heer, Koen
Van Kampen, Roel J. W.
Leijs, Maria B. L.
Thielen, Noortje
Westerman, Matthijs
Wu, Ka Lung
Ludwig, Inge
Issa, Djamila
Velders, Gerjo A.
Vekemans, Marie-Christiane
van de Donk, Niels W. C. J.
Timmers, Gert-Jan
Sonneveld, Pieter
Seefat, Maarten R.
Croon-de Boer, Fransien
Tick, Lidwine W.
van der Spek, Ellen
De Waal, Esther G. M.
Sohne, Maaike
Ypma, Paula F.
Nijhof, Inger S.
Klein, Saskia K.
Levin, Mark-David
Zweegman, Sonja
BLOOD, 2021, 138
[2] Phase 2 Trial of Daratumumab, Ixazomib, Lenalidomide and Modified Dose Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma
Kapoor, Prashant
Gertz, Morie A.
Laplant, Betsy
Malave, Gabriella C.
Wolfe, Eric
Muchtar, Eli
Siddiqui, Mustaqeem A.
Gonsalves, Wilson I.
Emanuel, Angie R.
Kourelis, Taxiarchis
Warsame, Rahma
Dingli, David
Buadi, Francis K.
Hayman, Suzanne R.
Leung, Nelson
Hwa, Yi L.
Hobbs, Miriam A.
Fonder, Amie
Dispenzieri, Angela
Lacy, Martha Q.
Rajkumar, S. Vincent
Kumar, Shaji K.
BLOOD, 2019, 134
[3] Phase 2 Trial of Ixazomib, Lenalidomide, Dexamethasone and Daratumumab in Patients with Newly Diagnosed Multiple Myeloma
Kumar, Shaji K.
Kapoor, Prashant
Laplant, Betsy
Muchtar, Eli
Buadi, Francis K.
Gonsalves, Wilson I.
Dingli, David
Go, Ronald S.
Warsame, Rahma
Kourelis, Taxiarchis
Lust, John A.
Lacy, Martha Q.
Dispenzieri, Angela
Hayman, Suzanne R.
Hwa, Yi
Fonder, Amie
Hobbs, Miriam
Leung, Nelson
Rajkumar, S. Vincent
Gertz, Morie A.
Wolfe, Eric
BLOOD, 2018, 132
[4] Ixazomib, Daratumumab, and Low-Dose Dexamethasone in Frail Patients With Newly Diagnosed Multiple Myeloma: The Hovon 143 Study
Stege, Claudia A. M.
Nasserinejad, Kazem
Van der Spek, Ellen
Bilgin, Yavuz M.
Kentos, Alain
Sohne, Maaike
van Kampen, Roel J. W.
Ludwig, Inge
Thielen, Noortje
Durdu-Rayman, Nazik
de Graauw, Nicole C. H. P.
van de Donk, Niels W. C. J.
de Waal, Esther G. M.
Vekemans, Marie-Christiane
Timmers, Gert Jan
van Der Klift, Marjolein
Soechit, Savita
Geerts, Paul A. F.
Silbermann, Matthijs H.
Oosterveld, Margriet
Nijhof, Inger S.
Sonneveld, Pieter
Klein, Saskia K.
Levin, Mark-David
Zweegman, Sonja
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (25) : 2758 - +
[5] AN OPEN-LABEL, PHASE 2 STUDY TO EVALUATE THE ORAL COMBINATION OF IXAZOMIB, CYCLOPHOSPHAMIDE AND DEXAMETHASONE IN TRANSPLANT-INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
Dimopoulos, M. A.
Grosicki, S.
Jedrzejczak, W.
Nahi, H.
Gruber, A.
Hansson, M.
Byrne, C.
Labotka, R.
Teng, Z.
Yang, H.
Grzasko, N.
Kumar, S.
HAEMATOLOGICA, 2017, 102 : 111 - 111
[6] Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial
Voorhees, Peter M.
Sborov, Douglas W.
Laubach, Jacob
Kaufman, Jonathan L.
Reeves, Brandi
Rodriguez, Cesar
Chari, Ajai
Silbermann, Rebecca
Costa, Luciano J.
Anderson, Larry D.
Nathwani, Nitya
Shah, Nina
Bumma, Naresh
Efebera, Yvonne A.
Holstein, Sarah A.
Costello, Caitlin
Jakubowiak, Andrzej
Wildes, Tanya M.
Orlowski, Robert Z.
Shain, Kenneth H.
Cowan, Andrew J.
Dinner, Shira
Pei, Huiling
Cortoos, Annelore
Patel, Sharmila
Lin, Thomas S.
Usmani, Saad Z.
Richardson, Paul G.
LANCET HAEMATOLOGY, 2023, 10 (10): : E825 - E837
[7] Phase 1/2 trial of ixazomib, cyclophosphamide, and dexamethasone for newly diagnosed multiple myeloma (NDMM).
Lacy, Martha
Bergsagel, P. Leif
LaPlant, Betsy
Halvorson, Alese
Buadi, Francis
Leung, Nelson
Go, Ronald S.
Dingli, David
Kapoor, Prashant
Gertz, Morie A.
Lin, Yi
Dispenzieri, Angela
Hwa, Yi Lisa
Fonder, Amie
Fonseca, Rafael
Hayman, Suzanne R.
Stewart, A. Keith
Mikhael, Joseph
Rajkumar, S. Vincent
Kumar, Shaji
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[8] Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial
Rajkumar, S. Vincent
Jacobus, Susanna
Callander, Natalie S.
Fonseca, Rafael
Vesole, David H.
Williams, Michael E.
Abonour, Rafat
Siegel, David S.
Katz, Michael
Greipp, Philip R.
LANCET ONCOLOGY, 2010, 11 (01): : 29 - 37
[9] An Open-label, Phase 2 Study to Evaluate the Oral Combination of Ixazomib, Cyclophosphamide, and Dexamethasone (ICd) in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (NDMM)
Dimopoulos, Meletios
Grosicki, Sebastian
Jedrzejczak, Wieslaw
Nahi, Hareth
Gruber, Astrid
Hansson, Markus
Byrne, Catriona
Labotka, Richard
Teng, Zhaoyang
Yang, Huyuan
Grzasko, Norbert
Kumar, Shaji
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 : S333 - S334
[10] Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial
Facon, Thierry
Kumar, Shaji K.
Plesner, Torben
Orlowski, Robert Z.
Moreau, Philippe
Bahlis, Nizar
Basu, Supratik
Nahi, Hareth
Hulin, Cyrille
Quach, Hang
Goldschmidt, Hartmut
O'Dwyer, Michael
Perrot, Aurore
Venner, Christopher P.
Weisel, Katja
Mace, Joseph R.
Raje, Noopur
Tiab, Mourad
Macro, Margaret
Frenzel, Laurent
Leleu, Xavier
Ahmadi, Tahamtan
Wang, Jianping
Van Rampelbergh, Rian
Uhlar, Clarissa M.
Tromp, Brenda
Delioukina, Maria
Vermeulen, Jessica
Usmani, Saad Z.
LANCET ONCOLOGY, 2021, 22 (11): : 1582 - 1596

← 1 2 3 4 5 →